v3.26.1
Segment Information and Geographic Data - Operating Segment Selected Financial Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:            
Revenue $ 243,600   $ 156,797   $ 457,866 $ 294,582
Costs and operating expenses:            
Cost of goods sold 23,572   18,603   44,368 36,471
Collaboration expenses 88,069   52,418   163,646 96,208
Direct research and development expenses by program:            
Research and development 40,899   18,753   68,374 38,078
Selling, general and administrative 63,866   46,863   125,017 90,393
Total operating expenses 216,406   136,637   401,405 261,150
Other income, net 3,951   2,717   7,365 5,010
Income before income taxes 31,145   22,877   63,826 38,442
Provision for income taxes (5,713)   (5,045)   (15,802) (12,071)
Net income 25,432 $ 22,592 17,832 $ 8,539 48,024 26,371
Other significant non-cash items:            
Share-based compensation expense 11,636   8,876   21,692 16,624
Non-cash lease expense 1,011   924   2,005 1,759
Deferred income taxes 2,661   2,644   7,184 5,637
ARCALYST            
Direct research and development expenses by program:            
Research and development 332   171   673 526
KPL-387            
Direct research and development expenses by program:            
Research and development 21,442   8,485   37,594 13,663
KPL-1161            
Direct research and development expenses by program:            
Research and development 766   370   1,721 470
Abiprubart            
Direct research and development expenses by program:            
Research and development 176   635   229 5,002
Unallocated research and development expenses            
Direct research and development expenses by program:            
Research and development 18,183   9,092   28,157 18,417
Product revenue, net            
Revenue:            
Revenue 243,600   156,797   $ 457,866 $ 294,582
Pharmaceutical            
Revenue:            
Revenue $ 243,600   $ 156,797